Portal de investigación
ESTUDIO PARA EVALUAR LA UTILIDAD CLÍNICA DEL CUESTIONARIO ESPECÍFICO DE CALIDAD DE VIDA RELACIONADA CON LA SALUD QLQGINET21 EN EL MANEJO DE PACIENTES CON TUMORES NEUROENDOCRINOS (NETS) GASTROINTESTINALES. ESTUDIO QUALINET.
Datos básicos
- Protocolo:
- IPS-ANT-2015-01
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2016
- Año de finalización:
Objetivos del proyecto
Observaciones: Estado Comité: ACTIVO
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Capdevila, J; (...); Manzano, JL
Meeting Abstract. 10.1016/j.annonc.2020.08.1373. 2020
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
Diaz-Beveridge, R; (...); Aparicio, J
Article. 10.1007/s12094-017-1720-4. 2018
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.
Jiménez-Fonseca P; (...); Grande E
Article. 10.18632/oncotarget.26380. 2018
Cancer worry at higher-risk sample of hereditary cancer in Spain.
Costa-Requena G, Richart-Aznar P, Segura-Huerta Á
Article. 10.1097/CEJ.0000000000000862. 2024
Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study
Gallego, J; (...); Benavent, M
Meeting Abstract. 2018
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; (...); Cross, Nicholas C. P.
Article. 10.1182/bloodadvances.2022008204. 2022
Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.
Costa-Requena, Gema; (...); Segura-Huerta, Angel
Article. 10.1097/CEJ.0000000000000734. 2022
Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
Ferrer-Avargues R; (...); Soto JL
Article. 10.1002/cac2.12134. 2021
Diagnostic demographics of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and usage patterns of local and systemic therapies (ERUDIT study)
Lopez, C; (...); Rodriguez-Villanueva, J
Meeting Abstract. 10.1016/j.annonc.2020.08.1412. 2020
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Capdevila, J.; (...); Manzano, J. L.
Article. 10.1038/s41467-023-38611-5. 2023
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Jimenez-Fonseca, Paula; (...); Garcia-Carbonero, Rocio
Article. 10.1159/000514808. 2021
Histological Differentiation Provides Useful, Additive and Independent Prognostic Information to Proliferation Index in G2 and G3 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Canovas, MS; (...); Garcia-Carbonero, R
Meeting Abstract. 2017
Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)
Ramirez-Calvo, M; (...); Lopez-Guerrero, JA
Article. 10.1186/s13053-019-0104-x. 2019
Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.
Vallejo Casas, Juan Antonio; (...); Orcajo-Rincon, Lorenzo
Article. 10.1530/ETJ-21-0111. 2022
Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia
Alonso-Gordoa, T.; (...); de La Cruz, G.
Meeting Abstract. 2022
Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program
Sevilla, I; (...); Grande, E
Article. 10.1186/s12885-016-2901-1. 2016
MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Baste Rotllan, N.; (...); Mesia, R.
Meeting Abstract. 10.1016/j.annonc.2023.09.999. 2023
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Nunez-Valdovinos, B; (...); Garcia-Carbonero, R
Article. 10.1634/theoncologist.2017-0364. 2018
Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.
del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.
Article. 10.3390/cancers14030584. 2022
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ortuzar, Ariana; (...); Osorio, Santiago
Article. 10.1007/s00277-022-05044-x. 2022
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).
Benavent M; (...); Gallego J
Article. 10.1186/s12955-021-01688-x. 2021
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A; (...); García-Carbonero R
Article. 10.1200/JCO.19.00980. 2019
Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
Fonfria, M; (...); Martinez-Duenas, E
Article. 10.3390/jpm11060548. 2021
Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
Costa-Requena G; (...); Segura-Huerta Á
Article. 10.1007/s12687-022-00580-5. 2022
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).
Castillón JC; (...); Plazas JG
Article. 10.1007/s12094-023-03205-6. 2023
Translational research in neuroendocrine tumors: pitfalls and opportunities
Capdevila, J; (...); Castano, JP
Review. 10.1038/onc.2016.316. 2017
Use Of Iodine-131 (RAI) For The Initial Diagnosis And Treatment Of Differentiated Thyroid Cancer (DTC) In Spain And Portugal (ERUDIT Study)
Casas, JV; (...); Orcajo, L
Meeting Abstract. 2020